

# Second World Indigenous Peoples' Conference on Viral Hepatitis

Individual response report

<b>Respondent Type:</b>	Anonymous	<b>Custom Data 1:</b>	
<b>Name:</b>		<b>Custom Data 2:</b>	
<b>Email:</b>		<b>Custom Data 3:</b>	
<b>IP Address:</b>	158.111.105.186	<b>Survey Started:</b>	05/08/2017, 06:41 PM GMT
<b>Country:</b>	United States	<b>Survey Ended:</b>	05/08/2017, 07:12 PM GMT

Second World Indigenous Peoples' Conference on Viral Hepatitis - 2017 Call for Abstracts Submission Form

Submission Guidelines

Review and Selection Process

Scholarships

Abstract Form

## 1. Primary Presenter Information

PLEASE NOTE: As the primary presenter - you will be the point of contact for correspondence with the conference coordinator regarding logistics and coordination of the presentation.

Name	Emily Mosites
Credentials (ex: RN, MPH, Student)	PhD MPH
Title	Epidemic Intelligence Service Officer
Organization	Centers for Disease Control and Prevention
Address	4055 Tudor Centre Dr
City/Town	Anchorage
State	AK
Zip	99508
Email Address	lwx7@cdc.gov
Phone Number	9073460570

## 2. Other Presenters

Name	None
Credentials (ex: RN, MPH, Student)	NA
Title	NA
Organization	NA
Address	NA
City/Town	NA
State	NA
Zip	NA
Email Address	NA
Phone Number	NA

### 3. Other Presenters

Name	None
Credentials (ex: RN, MPH, Student)	NA
Title	NA
Organization	NA
Address	NA
City/Town	NA
State	NA
Zip	NA
Email Address	NA
Phone Number	NA

### 4. Other Presenters

Name	None
Credentials (ex: RN, MPH, Student)	NA
Title	NA
Organization	NA
Address	NA
City/Town	NA
State	NA
Zip	NA
Email Address	NA
Phone Number	NA

5. Please confirm that you are comfortable presenting in English.

Yes

6. Would you like to be considered for a scholarship?

No

## 7. Presentation Title:

Hepatitis A vaccine response 22 years after vaccination

## 8. Presentation Category (select from the options below):

Data – burden of disease, prevalence, incidence, immunisation, treatment and outcomes, strategies for getting these data.

Research exemplars – current, recent research.

## 9. Abstract (Session Description)

Please do not exceed 500 words. Please provide an overview of the content that you plan to share in your presentation.

Emily Mosites<sup>1</sup>, Prabhu Gounder<sup>1</sup>, Mary Snowball<sup>2</sup>, Julie Morris<sup>1</sup>, Philip Spradling<sup>3</sup>, Noele Nelson<sup>3</sup>, Lisa Bulkow<sup>1</sup>, Michael Bruce<sup>1</sup>, Brian McMahon<sup>2</sup>

<sup>1</sup> Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention

<sup>2</sup> Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium

<sup>3</sup> Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention

In the United States, the incidence of hepatitis A virus (HAV) infection has been markedly reduced through childhood vaccination. However, the duration of immunogenicity for the hepatitis A vaccine is not known. Here we report on the 22 year follow-up time point of a cohort of Alaskan children who, at aged 3-6 years, were randomized to three different vaccine schedules: A) 0,1,2 months; B) 0,1,6 months; and C) 0,1,12 months. We compared the antibody titers across these three schedules using both raw and imputed datasets to account for missing data. Among 46 participant available for follow-up, 40 ( 87%) maintained protective levels of anti-hepatitis A antibody. Those participants in schedule A had significantly lower antibody titers than those in schedules B or C, which was consistent in models using both raw and imputed datasets. These results indicate that participants maintained high levels of antibody protection against HAV 22 years after vaccination and that a supplemental booster dose is not yet necessary.

## 10. Presentation Preference Type:

Plenary (whole group, ~150 - 200 people)

Workshop Session - Presentation Style (30 - 50 people)

Other: Any session is fine

## 11. Learning objectives: Please specify which of the following conference goals relates best to your session (select all that apply):

Describe how to discuss and document our knowledge of the prevalence of hepatitis viruses in Indigenous Peoples across the globe.

Identify ways to profile and summarize current national activities.

## 12. If your abstract were to be selected for oral presentation please specify 3-5 SMART (Specific, Measurable, Attainable, Realistic, Trackable) objectives for your presentation that meet the conference goals.

The objectives for this presentation are as follows:

1) To convey the historical burden of Hepatitis A among Alaska Native people

2) To describe the ways in which study participation levels might affect our conclusions about the effectiveness of the Hepatitis A vaccine

3) To communicate the long term effectiveness of the Hepatitis A vaccine

13. Primary Presenter Biography (please introduce yourself in 100-200 words):

Emily Mosites is an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention in Anchorage, AK. She works on invasive bacterial disease and hepatitis with an interest in alleviating health disparities.

14. Presenter #2 Biography (please introduce yourself in 100-200 words):

None

15. Presenter #3 Biography (please introduce yourself in 100-200 words):

None

16. Presenter #4 Biography (please introduce yourself in 100-200 words):

None